GlassScriptPhysician profile
John O Gernert
NPI 1609808419
$8,411.41
in general payments reported to CMS, 2019-2025
40 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $1,167 · 2021: $2,235 · 2022: $2,601 · 2023: $817 · 2024: $702 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,859.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,058.94 | 2019-2024 | Proclaim, Eterna, Ionicrf |
| Abbvie INC. | $666.18 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $324.03 | 2020-2021 | |
| Nevro Corp. | $279.44 | 2019-2024 | Senza |
| Genzyme Corporation | $218.40 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.64 | 2019-2021 | |
| Vertos Medical, INC. | $169.29 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $140.63 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $123.25 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $108.19 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $94.39 | 2020-2021 | |
| Greenwich Biosciences, INC. | $93.87 | 2019-2020 | |
| Zyla Life Sciences, INC. | $88.66 | 2019-2020 | |
| Globus Medical, INC. | $86.71 | 2025 | Senza |
| Avanir Pharmaceuticals, INC. | $70.13 | 2020-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $70.10 | 2020-2021 | |
| Medtronic, INC. | $59.95 | 2022-2025 | Inceptiv |
| Amgen INC. | $45.74 | 2019-2021 | |
| Virtus Pharmaceuticals LLC | $44.80 | 2021 | |
| Boston Scientific Corporation | $34.89 | 2020 | |
| Csl Behring | $34.06 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $31.74 | 2021 | |
| Redhill Biopharma INC. | $31.07 | 2021 | |
| Radius Health, INC. | $29.07 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $26.58 | 2022 | |
| Merck Sharp & Dohme LLC | $26.06 | 2020-2021 | |
| Grt US Holding, INC. | $25.02 | 2021 | |
| Harmony Biosciences LLC | $23.06 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $23.05 | 2025 | |
| Merz North America, INC. | $22.39 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $20.47 | 2020 | |
| Depuy Synthes Sales INC. | $20.45 | 2024 | Confidence Spinal Cement System |
| Averitas Pharma INC. | $20.03 | 2023 | Qutenza |
| Upsher-Smith Laboratories LLC | $18.70 | 2019 | |
| Indivior INC. | $17.03 | 2021 | |
| Tanabe Pharma America, INC. | $14.99 | 2020 | |
| Lilly USA, LLC | $14.80 | 2021 | |
| Zogenix INC. | $13.16 | 2021 | |
| Pfizer INC. | $11.73 | 2019 | |
| Neurelis, INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gernert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.